Tumor-Agnostic Therapy Video Perspectives

In this video series, Patrick Ott, MD, PhD, director of clinical sciences at the Center for Immuno-Oncology Clinical, director of the Melanoma Disease Center and senior physician at Dana-Farber Cancer Institute, and associate professor of medicine at Harvard Medical School, talked about:

• the potential of personalized vaccines that can target mutations “that are present in every tumor;”
• tumor-agnostic therapies for NTRK mutations and PD-1 inhibition;
• why education about these drugs “applies to community oncologists just as much as it applies to a more specialized academic oncologist;”
• his uncertainty about “how broadly these agents will be used in oncology;”
• considerations for future research;
• ongoing trials on using personalized vaccines in the melanoma space; and
• the differences between potentially identifying patients for personalized vaccines that target mutations vs. identifying patients for other tumor-agnostic therapies.